Transungual delivery of ketoconazole using novel lacquer formulation.

[1]  G. Fan,et al.  In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. , 2013, International journal of antimicrobial agents.

[2]  S. Feldman,et al.  Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study. , 2013, Journal of drugs in dermatology : JDD.

[3]  K. A. Walters,et al.  The human nail--barrier characterisation and permeation enhancement. , 2012, International journal of pharmaceutics.

[4]  S. N. Murthy,et al.  Ungual and Transungual drug delivery , 2012, Drug development and industrial pharmacy.

[5]  T. Walsh,et al.  Systemically Administered Antifungal Agents , 1992, Drugs.

[6]  Gregory M. Peterson,et al.  Toenail onychomycosis: an important global disease burden , 2010, Journal of clinical pharmacy and therapeutics.

[7]  Aditya K. Gupta,et al.  Onychomycosis therapy: past, present, future. , 2010, Journal of drugs in dermatology : JDD.

[8]  G. Betz,et al.  Investigation of different formulations for drug delivery through the nail plate. , 2010, International journal of pharmaceutics.

[9]  D. Monti,et al.  Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity , 2010, The British journal of dermatology.

[10]  H. Maibach,et al.  Transungual drug delivery: current status. , 2010, International journal of pharmaceutics.

[11]  G. Kasting,et al.  Effect of hydration on the permeation of ketoconazole through human nail plate in vitro. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  B. Elewski,et al.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality , 2005, Therapeutics and clinical risk management.

[13]  M. Lecha,et al.  Epidemiology and clinical classification of onychomycosis , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  J. Faergemann,et al.  Epidemiology, clinical presentation and diagnosis of onychomycosis. , 2003, The British journal of dermatology.

[15]  Aditya K. Gupta,et al.  In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity , 2003, The British journal of dermatology.

[16]  H. Maibach,et al.  Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. , 2003, Journal of pharmaceutical sciences.

[17]  S. Murdan.  Drug delivery to the nail following topical application. , 2002, International journal of pharmaceutics.

[18]  J. Zatz,et al.  Investigation of nail permeation enhancement by chemical modification using water as a probe. , 2002, Journal of pharmaceutical sciences.

[19]  H. Maibach,et al.  Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. , 2002, Journal of pharmaceutical sciences.

[20]  P. Krupp,et al.  Safety of oral terbinafine : Results of a postmarketing surveillance study in 25 884 Patients , 1997 .

[21]  J. Marty.  Amorolfine nail lacquer: a novel formulation , 1995 .

[22]  D. Faulds,et al.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. , 1992, Drugs.

[23]  S. Cullen,et al.  Ketoconazole and griseofulvin in the treatment of toenail dermatophyte onychomycosis , 1987 .

[24]  J. Cutsem.  The antifungal activity of ketoconazole , 1983 .